Merus (NASDAQ:MRUS – Get Free Report) saw a large drop in short interest in the month of February.As of February 15th, there was short interest totalling 6,640,000 shares, a drop of 13.5% from ...

Shares of Merus stock opened at $44.64 on Monday. Merus has a 12-month low of $37.77 and a 12-month high of $61.61. The company has a market cap of $3.06 billion, a P/E ratio of -11.30 and a beta ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company ...

Merus N.V. (NASDAQ:MRUS), a biotechnology company specializing in innovative antibody-based therapies with a market capitalization of $2.75 billion, has garnered significant attention from ...

Stifel Nicolaus analyst Bradley Canino maintained a Buy rating on Merus (MRUS – Research Report) today and set a price target of $93.00. The company’s shares closed yesterday at $46.22.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific ...

In September 2024, Merus announced the first patient was dosed in LiGeR-HN1, a phase 3 trial evaluating the efficacy and safety of petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m ...

Piper Sandler initiated coverage of Merus (MRUS) with an Overweight rating and $84 price target The firm views the company’s EGFRxLGR5 bispecific, petosemtamab, as “significantly de-risked ...

SINGAPORE: DBS services, including mobile banking, ATMs and NETS, have been restored after an overnight disruption on Saturday (Mar 8). According to outage tracking site, Downdetector.com ...

Merus shares rise after the FDA grants Breakthrough Therapy designation for petosemtamab in combination with pembrolizumab for head. Investor optimism grows as the designation accelerates ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative ...

Feb. 27, 2025(Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics ®, Triclonics ...